| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | Uveal Melanoma | Recruiting |
| Phase 2/3 | |||
| NCT05987332 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic… | Metastatic Uveal Melanoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT05907954 | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | Uveal Melanoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Metastatic Uveal Melanoma | Recruiting |
| NCT07174583 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | Small-cell Lung Cancer | Recruiting |
| Phase 1 | |||
| NCT07540572 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574… | ER+, HER 2- Breast Cancer | Recruiting |
| NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors… | Esophageal Squamous Cell Carcinoma | Recruiting |
| NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | NSCLC Adenocarcinoma | Recruiting |
| NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Solid Tumor | Active, Not Recruiting |
| NCT05787587 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | Advanced or Metastatic Solid Tumors | Active, Not Recruiting |